GLP-1RAs May Yield Lower Risk for IBD in Type 2 Diabetes

['Oladimeji Ewumi', '.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright'] News Archive - Endocrinology Advisor 2025-09-24 05:47:18

Participants were divided into 2 groups according to use of basal insulin or GLP-1RAs. “ These findings suggest GLP-1RAs may help reduce IBD risk in this population. Compared with basal insulin users, GLP-1RA users had a significantly lower risk of developing IBD (hazard ratio [HR], 0.725; 95% CI, 0.564-0.931) and hospitalization (HR, 0.144; 95% CI, 0.140-0.148). GLP-1RA users also showed a lower risk for hospitalization than SGLT2i users (HR, 0.792; 95% CI, 0.775-0.809). These findings suggest GLP-1RAs may help reduce IBD risk in this population.”